The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis

European Journal of Surgical Oncology

Volumn 41, Issue 4, 2015, Pages 450-456

  Wang, A ^a   Wang, H Y ^a   Liu, Y ^a   Zhao, M C ^a   Zhang, H J ^b   Lu, Z Y ^a   Fang, Y C ^a   Chen, X F ^a,b   Liu, G T ^a  

^a SHANGHAI PULMONARY HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Differentiation; NSCLC; Overall survival; Prognostic; Programmed cell death ligand 1

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ADENOCARCINOMA; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; GENDER; GENE EXPRESSION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; CANCER GRADING; GENETICS; LUNG TUMOR; META ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL RATE;

ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 84929939531     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2015.01.020     Document Type: Review

References (42)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2013;381:1987-2015.
3. Parums DV. Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc) 2014;50:503-25.
4. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
5. Guilbert JJ. The world health report 2002 e reducing risks, promoting healthy life. Educ Health (Abingdon) 2003;16:230.
6. Yang CY, Lin MW, Chang YL, et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014;50:1361-9.
7. Langer CJ. Emerging immunotherapies in the treatment of Non-Small Cell Lung Cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2014 (in press).
8. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-9.
9. Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014;21:80-9.
10. Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002;169:5538-45.
11. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77.
12. Shi L, Chen S, Yang L, et al. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 2013;6:74.
13. Zhang Y, Zhang J, Xu K, et al. PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. Hepatogastroenterology 2013;60:1766-72.
14. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361-70.
15. Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 2014;26:104-11.
16. Jilaveanu LB, Shuch B, Zito CR, et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer 2014;5:166-72.
17. Maine CJ, Aziz NH, Chatterjee J, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother 2014;63: 215-24.
18. Merelli B, Massi D, Cattaneo L, et al. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014;89:140-65.
19. Liu Y, Carlsson R, Ambjorn M, et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci 2013;33:14231-45.
20. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
21. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
22. Mu C-Y, Huang J-A, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2010;28:682-8.
23. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 2012;98:751-5.
24. Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014;7:567-73.
25. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-16.
26. Azuma K, Ota K, Kawahara A, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014;25:1935-40.
27. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
30. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of betweenstudy heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008;37:1148-57.
31. Vinay K, Abbas AL, Fauston N. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia: WB Saunders; 2005.
32. Sun Z, Aubry MC, Deschamps C, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg 2006;131:1014-20.
33. Coate LE, John T, Tsao MS, et al. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009;10:1001-10.
34. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on nonsmall cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-100.
35. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006;119:317-27.
36. Tsushima F, Yao S, Shin T, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007;110:180-5.
37. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
38. Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D, et al. Tumorinduced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol 2012;2012:741741.
39. Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J 2014;20:281-9.
40. Hamid O, Carvajal RD. Anti-programmed death-1 and antiprogrammed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 2013;13:847-61.
41. Aranda F, Vacchelli E, Eggermont A, et al. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27297.
42. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369: 134-44.